Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) was the target of a large growth in short interest in July. As of July 14th, there was short interest totalling 1,973,961 shares, a growth of 46.2% from the June 30th total of 1,350,336 shares. Currently, 10.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,029,433 shares, the short-interest ratio is currently 1.0 days.
An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Susquehanna International Group LLP bought a new stake in shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the second quarter, according to its most recent 13F filing with the SEC. The firm bought 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned 3.84% of Interpace Diagnostics Group as of its most recent SEC filing. Hedge funds and other institutional investors own 1.83% of the company’s stock.
Separately, Maxim Group initiated coverage on shares of Interpace Diagnostics Group in a research note on Tuesday. They issued a “buy” rating and a $5.00 price objective for the company.
Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings results on Thursday, August 10th. The business services provider reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $3.86 million for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.14% and a negative net margin of 37.14%.
TRADEMARK VIOLATION NOTICE: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/08/19/short-interest-in-interpace-diagnostics-group-inc-nasdaqidxg-expands-by-46-2-updated-updated.html.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.
What are top analysts saying about Interpace Diagnostics Group Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Interpace Diagnostics Group Inc. and related companies.